Pfizer, Inc.

PFE

US7170811035

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:01:23 2024-05-13 pm EDT			5-day change	1st Jan Change
28.44 ^USD	+1.54%		+0.99%	-1.22%

May. 13	Global markets live: Pfizer, Chevron, Amazon, Booking, Apple, Novavax, SoftBank...
May. 13	France Secures $16 Billion From Microsoft, Amazon and Others at Foreign Investment Summit -- 2nd Update	DJ

PFIZER INC : Goldman Sachs gives a Neutral rating

January 08, 2021 at 12:06 pm EST

In his latest research note, analyst Terence Flynn confirms his recommendation. The broker Goldman Sachs is keeping its Neutral rating. The target price is unchanged at USD 40.

Latest news about Pfizer, Inc.

Global markets live: Pfizer, Chevron, Amazon, Booking, Apple, Novavax, SoftBank...	May. 13
France Secures $16 Billion From Microsoft, Amazon and Others at Foreign Investment Summit -- 2nd Update	May. 13	DJ
France Secures $16 Billion From Microsoft, Amazon and Others at Foreign Investment Summit -- Update	May. 13	DJ
Pfizer, AstraZeneca, Morgan Stanley Pledge Investments, Jobs to France	May. 13	MT
Redburn Atlantic Adjusts Price Target on Pfizer to $27 From $26, Keeps Neutral Rating	May. 13	MT
France Secures Billions at Foreign Investment Summit	May. 13	DJ
Pfizer to Invest EUR500 Million for Research, Development in France	May. 13	MT
France gets $16 billion of foreign investments as part of 'Choose France' event	May. 13	RE
Pfizer and AstraZeneca announce new investments of nearly $1 billion in France	May. 12	RE
Pfizer announces 500 million euros investment in France	May. 12	RE
Novavax Surges on $1.2 Billion Sanofi Vaccine Deal	May. 10	MT
HLS Therapeutics Meets Q1 Earnings Forecast, But Misses on Revs; Lowers 2024 Vascepa Guidance	May. 09	MT
Sector Update: Health Care Stocks Softer Late Afternoon	May. 08	MT
Sector Update: Health Care Stocks Slipping Wednesday Afternoon	May. 08	MT
Pfizer Agrees to Settle 10,000 Zantac Lawsuits Over Alleged Cancer Risks, Bloomberg Reports	May. 08	DJ
Pfizer to Settle More Than 10,000 Zantac Cancer Lawsuits	May. 08	MT
Pfizer to Settle More Than 10,000 Zantac Cancer Lawsuits	May. 08	MT
Pfizer Reportedly Agrees to Settle Over 10,000 Zantac Cancer Lawsuits	May. 08	MT
Pfizer to Settle More Than 10,000 Zantac Cancer Lawsuits, Bloomberg Says	May. 08	MT
Pfizer agrees to settle more than 10,000 Zantac cancer lawsuits - Bloomberg News	May. 08	RE
Pfizer Inc. Receives Authorization from Health Authority for the First Dual Indication Vaccine Approved in Hong Kong	May. 08	CI
Evonik expects Q2 core profit in line with Q1, confirms 2024 outlook	May. 08	RE
Pfizer reports patient death in Duchenne gene therapy study	May. 07	RE
BioNTech Swings to First-Quarter Loss as Lower COVID-19 Commercial Sales Dents Topline	May. 06	MT
Pfizer: Citi analyst appointed Chief Strategy Officer	May. 06	CF

Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (72.8%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (13.8%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (12.1%); - other (1.3%). At the end of 2022, the group had more than 35 manufacturing sites worldwide. Net sales are distributed geographically as follows: the United States (42.3%), Europe (21.9%) and other (35.8%).

Sector

Pharmaceuticals

Calendar

2024-05-31 - American Society of Clinical Oncology Annual Meeting - Abstract No: LBA8503

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Pfizer, Inc: A cycle for nothing?

December 14, 2023 at 10:58 am EST

Albert Bourla, Pfizer CEO (full interview): mRNA, acquisitions, weight-loss drugs

October 31, 2023 at 04:50 pm EDT

More Strategies

Ratings for Pfizer, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

28.44 USD

Average target price

31.94 USD

Spread / Average Target

+12.30%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PFIZER, INC.	-1.22%	159B
ELI LILLY AND COMPANY	+29.98%	684B
NOVO NORDISK A/S	+30.34%	568B
JOHNSON & JOHNSON	-3.52%	361B
MERCK & CO., INC.	+18.59%	329B
ABBVIE INC.	+4.07%	284B
ASTRAZENECA PLC	+16.21%	240B
NOVARTIS AG	+9.66%	208B
ROCHE HOLDING AG	-6.83%	200B
AMGEN INC.	+7.09%	166B

Other Pharmaceuticals

Pfizer, Inc.

Equities

PFE

US7170811035

Pharmaceuticals

PFIZER INC : Goldman Sachs gives a Neutral rating

Latest news about Pfizer, Inc.

Chart Pfizer, Inc.

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Pfizer, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals